An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

This early-stage study tests a new drug called Oba01 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has continued to grow after prior treatment. Oba01 targets a protein called DR5 that is found on cancer cells and can trigger cell death. **You may be eligible if...** - You are between 18 and 75 years old - You have locally advanced or metastatic NSCLC confirmed by biopsy - Your cancer has progressed after prior systemic treatment - You have measurable disease visible on imaging - Your overall health is good (ECOG 0 or 1) - Your organ function is adequate - You agree to use contraception for 6 months after last treatment if of childbearing potential **You may NOT be eligible if...** - You have previously been treated with a DR5-targeted drug or a specific type of antibody-drug conjugate - You have brain metastases that are active, symptomatic, or require steroids - You have active hepatitis C, HIV, or active hepatitis B - You are pregnant, breastfeeding, or lactating Talk to your doctor to see if this trial is right for you.